ArticleJournal of translational medicine2015
Metformin as a potential combination therapy with existing front-line antibiotics for Tuberculosis.
Article in Journal of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05215990 (Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis), which is not on this map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis: A Randomized Controlled Trial
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis.European journal of clinical pharmacology · 2020 · on this mapPooled it
- Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review.BMC infectious diseases · 2019 · on this mapPooled it
- Relationship between metformin use and mortality in tuberculosis patients with diabetes: a nationwide cohort study.The Korean journal of internal medicine · 2024Article
- Metformin improvesFrontiers in immunology · 2024Article
- Repurposing an Antioxidant to KillBiomolecules · 2023Article
- Metformin as adjunctive therapy in combination with multidrug treatment for multibacillary leprosy: A protocol for a randomized double-blind, controlled Phase 2 trial in Indonesia (MetLep Trial).Wellcome open research · 2023Article
- Metformin reverse minocycline to inhibit minocycline-resistant Acinetobacter baumannii by destroy the outer membrane and enhance membrane potential in vitro.BMC microbiology · 2022Article
- AllCurrent research in immunology · 2022Review
- Anti-diabetics and antimicrobials: Harmony of mutual interplay.World journal of diabetes · 2021Review
- Review of the Effectiveness of Various Adjuvant Therapies in TreatingInfectious disease reports · 2021Review
- Metformin as a potential protective therapy against tuberculosis in patients with diabetes mellitus: A retrospective cohort study in a single teaching hospital.Journal of diabetes investigation · 2021Article
- Effect of anti-tuberculosis treatment on the systemic levels of tissue inhibitors of metalloproteinases in tuberculosis - Diabetes co-morbidity.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- Diabetes Mellitus and Tuberculosis Treatment Outcomes in Pune, India.Open forum infectious diseases · 2021Article
- Metformin as a Potential Adjuvant Antimicrobial Agent Against Multidrug Resistant Bacteria.Clinical pharmacology : advances and applications · 2021Article
- Article
- Therapeutic host-directed strategies to improve outcome in tuberculosis.Mucosal immunology · 2020Review
- Ion Transport Modulators as Antimycobacterial Agents.Tuberculosis research and treatment · 2020Article
- Metformin as Host-Directed Therapy for TB Treatment: Scoping Review.Frontiers in microbiology · 2020Article
- Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus.Nature reviews. Endocrinology · 2019Review
- Pulmonary tuberculous cavities in diabetic patients: Glycemic control is still the dominant factor despite the emerging role of metformin.Journal of the Chinese Medical Association : JCMA · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb) remains a global health concern. The evolution of various multi-drug resistant strains through genetic mutations or drug tolerant strains through bacterial persistence renders existing antibiotics ineffective. Hence there is need for the development of either new antibiotics or rationalizing approved drugs that can be utilized in combination with existing antibiotics as a therapeutic strategy. A comprehensive systems level mapping of metabolic complexity in Mtb revels a putative role of NDH-I in the formation of bacterial persistence under the influence of front-line antibiotics. Possibilities of targeting bacterial NDH-I with existing FDA approved drug for type-II diabetes, Metformin, along with existing front-line antibiotics is discussed and proposed as a potential combination therapy for TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.